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Abstract
Background: The origin and the contribution of breast tumor heterogeneity to its progression are not clear. We
investigated the effect of a growing orthotopic tumor formed by an aggressive estrogen receptor (ER)-negative breast
cancer cell line on the metastatic potential of a less aggressive ER-positive breast cancer cell line for the elucidation of how
the presence of heterogeneous cancer cells might affect each other’s metastatic behavior.
Methods: ER positive ZR-75-1/GFP/puro cells, resistant to puromycin and non-tumorigenic/non-metastatic without
exogenous estrogen supplementation, were injected intracardiacally into mice bearing growing orthotopic tumors, formed
by ER negative MDA-MB-231/GFP/Neo cells resistant to G418. A variant cell line B6, containing both estrogen-dependent
and -independent cells, were isolated from GFP expressing cells in the bone marrow and re-inoculated in nude mice to
generate an estrogen-independent cell line B6TC.
Results: The presence of ER negative orthotopic tumors resulted in bone metastasis of ZR-75-1 without estrogen
supplementation. The newly established B6TC cell line was tumorigenic without estrogen supplementation and resistant to
both puromycin and G418 suggesting its origin from the fusion of MDA-MB-231/GFP/Neo and ZR-75-1/GFP/puro in the
mouse bone marrow. Compared to parental cells, B6TC cells were more metastatic to lung and bone after intracardiac
inoculation. More significantly, B6TC mice also developed brain metastasis, which was not observed in the MDA-MB-231/
GFP/Neo cell-inoculated mice. Low expression of ERa and CD24, and high expression of EMT-related markers such as
Vimentin, CXCR4, and Integrin-b1 along with high CD44 and ALDH expression indicated stem cell-like characteristics of
B6TC. Gene microarray analysis demonstrated a significantly different gene expression profile of B6TC in comparison to
those of parental cell lines.
Conclusions: Spontaneous generation of the novel hybrid cell line B6TC, in a metastatic site with stem cell-like properties
and propensity to metastasize to brain, suggest that cell fusion can contribute to tumor heterogeneity.
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Introduction
Breast cancer is the most frequent malignant disease in women,
affecting 1 in 8 North American women throughout their lifetime
and is the second leading cause of cancer-related deaths in U.S.
[1]. Mechanisms for the frequent failure of chemotherapy,
endocrine therapy or immunotherapy to successfully treat breast
cancer are elusive and under active investigation.
Breast cancer cells in a patient are heterogeneous, differing in
their apparent state of differentiation and malignant potential.
Random mutational events and/or epigenetic changes of cancer
cells followed by the selection of more malignant variants or
acquisition of stem cell like properties has been believed to be the
mechanism for tumor progression and consequently for the
generation of heterogeneous tumor cell population. An alternative
cell fusion model of cancer progression and metastasis has also been
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epigenetic alterations in a single cell lineage [2,3]. Rapid acquisition
of metastatic phenotypes has recently been shown through fusion
between tumor cells [4] or between tumor cells and bone marrow
derived cells [5] indicating a potentially important role of cell fusion
in the progression and phenotypic diversity of cancer.
One potential contribution of the heterogeneity to tumor
progression is the production of various secreted factors from
different types of tumor cells, which may promote malignant
behavior among themselves. An emerging paradigm is that tumors
are able to produce factors that induce the formation of so-called
pre-metastatic niches in organs where metastases will ultimately
develop [6]. The present study was initiated to determine whether
a growing orthotopic tumor formed by an aggressive ER-negative
breast cancer cell line might affect the metastatic potential of a less
aggressive ER-positive breast cancer cell line. To test this
hypothesis, five-week-old female nude mice were injected
orthotopically with highly aggressive ER-negative human breast
cancer MDA-MB-231/GFP/Neo cells. After three weeks, less
aggressive human breast cancer ER-positive ZR-75-1/GFP/puro
cells were inoculated into these tumor bearing mice via intra-
cardiac (IC) route. Puromycin resistant metastatic ZR-75-1/GFP/
puro cells were obtained from the bone marrow of one mouse and
established as a variant cell line called B6. B6 cells were found to
be a heterogeneous population containing both estrogen-depen-
dent and -independent cells when tested for their tumorigenicity in
nude mice with or without estrogen supplementation. We show
that the estrogen-independent cells, isolated from an estrogen-
independent tumor, is a novel hybrid cell line generated
spontaneously in a metastatic site (mouse bone marrow), which
has propensity to metastasize to brain in addition to lung and
bone. The cell line, named B6TC, exhibits phenotypes of
CD44
hiCD24
lo, high expression of ALDH, and formation of
mammospheres, all of which have been shown to be properties of
breast cancer stem cells. Our results indicate that the secreted
factors from the highly aggressive growing tumors might have
induced an appropriate environment for the less aggressive tumor
cells to metastasize in the bone resulting in the formation of the
hybrid cell line, which could cause additional tumor heterogeneity.
Results
Generation of bone metastasis from less aggressive
breast cancer cells in the presence of highly aggressive,
orthotopic tumors
Experimental evidence indicates that soluble factors produced by
aggressive cancer cells may generate metastatic niches for less
aggressive cancer cells, and we were interested to determine if
growing orthotopic tumor formed by an aggressive ER-negative
breast cancer cell line could affect the metastatic potential of a less
aggressive ER-positive breast cancer cell line. Five-week-old female
athymic nude mice (five in each group) were inoculated orthotop-
ically into the mammary fat pad with ER-negative and metastatic
MDA-MB-231/GFP/Neo or MDA-MB-435-F-L/GFP cells. ER-
positive human breast cancer ZR-75-1/GFP/puro cells, which we
know are non-tumorigenic and non-metastatic without exogenous
estrogen supplementation in nude mice, were then injected
intracardiacally into mice bearing growing tumors formed by
MDA-MB-231 or MDA-MB-435-F-L cells two and half weeks after
the orthotopic inoculation. We found ZR-75-1/GFP/puro cells in
bone marrow of two mice bearing growing MDA-MB-231/GFP/
Neo orthotopic tumors and one mouse bearing growing MDA-MB-
435-F-L/GFP orthotopic tumors in the absence of estrogen
supplementation, but not in control mice without orthotopic
tumors. The metastatic ZR-75-1/GFP/puro cells were flushed
out of the bone marrows and established as variant cell lines. Two
variant lines, called B4 and B6, from two mice bearing MDA-MB-
435-F-L/GFP or MDA-MB-231/GFP/Neo tumors respectively
were further characterized for their ER expression, tumorigenicity
in the mouse mammary fat pad, and metastatic potential to lung
and bone through intracardiac injection in the presence or absence
of estrogen supplementation. B4 cells expressed more ERa in
Western immunoblot analysis compared to B6 (Fig. 1A). Surpris-
ingly, although both variants were isolated from bone marrow and
they showed the same anchorage-dependent and -independent
growth property in vitro (data not shown),B6 was significantly more
tumorigenicthanB4bothwithorwithoutestrogensupplementation
in vivo (Fig. 1B). In fact, B6 was more or equally tumorigenic and
metastatic to lung (Fig. 1C) in the absence of estrogen supplemen-
tation as B4 in the presence of estrogen supplementation. Like
parental ZR-75-1 cell, B4 is not tumorigenic and metastatic without
estrogen supplementation (Fig. 1B).
Isolation and characterization of an estrogen-
independent ZR-75-1 cell line
The B6 cells were found to contain both estrogen-dependent
and –independent cells when they were orthotopically injected
into female nude mice with or without estrogen supplementation
(Fig. 1B). We isolated and established a cell line from a tumor with
estrogen supplementation and called it B6TE and another cell line
from a tumor without estrogen supplementation and called it
B6TC. More interestingly, both B6 and B6TC cells were found to
contain cells resistant to both puromycin and G418. The majority
of B6TC cells were resistant to both antibiotics whereas a small
percent of B6 cells were resistant to both antibiotics suggesting that
the double resistant cells were likely derived from a fusion cell
containing genetic materials of both MDA-MB-231/GFP/Neo
and ZR-75-1/GFP/puro cells. We mixed MDA-MB-231/GFP/
Neo and ZR-75-1/GFP/puro cells in culture for more than one
month and failed to obtain cells with resistance to both puromycin
and G418 and therefore concluded that the fusion took place in
the mouse bone marrow. To further strengthen our inference
about the chimeric nature of the B6TC cell line, we performed
gene microarray analysis of all three cell lines and generated a heat
map (Fig. S1A) to show the level of expression of different genes
across these three cell lines. The results from triplicate microarray
chips revealed that B6TC cell has a different gene expression
profile from those of its two parent cell lines even though it appears
more closely related to the MDA-MB-231 cell than to the ZR-75-1
cell. Detailed analysis of gene expression levels revealed that
significant differences in gene expression at the false discovery rate
(FDR) of equal or smaller than 0.05 among all three cell lines was
detected by 7,491 gene probes (Fig. S1B). In addition, significantly
different levels of gene expression for B6TC were detected by 483
probes, for MDA-MB-231 were detected by 445 probes, and for
ZR-75-1 were detected by 2,624 probes (Fig. S1B). Consistent with
our conclusion that B6TC cell is derived from MDA-MB-231 cell,
both cell lines contain a mutant p53
R280K (Fig. S2), which is
known to be associated with MDA-MB-231 cell [7].
Morphologically the B6TC cells appear spindle-like, similar to
MDA-MB-231, and differ from their parental ZR-75-1 cells,
which are cobblestone-like (Fig. 2A). However, unlike MDA-MB-
231 cells, which do not express ERa, B6TC cells express a low
level of ERa, which is highly expressed in ZR-75-1 and B6 cells
(Fig. 2B). Immunocytochemical staining of ERa revealed that
while parental ZR-75-1 cells expressed a uniformly high level of
ERa and MDA-MB-231 cells did not express ERa, B6TC cells are
heterogeneous in ERa expression with the majority of cells
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estrogen-responsive promoter-luciferase reporter construct, lucif-
erase activity was not detectable in B6TC cells treated with or
without estradiol, whereas other ERa positive cell lines showed
high levels of luciferase activity, which was further stimulated after
treatment with estrogen (Fig. 2D) suggesting that the ERa-
expressing cells of the B6TC line are too few to generate a
detectable response.
Growth properties of B6TC cells in vitro and in vivo
The B6TC cells grew slower on plastic compared to B6 and
B6TE cells (Fig. 3A). When suspended in soft agarose, B6TC cells
also formed smaller and fewer colonies than ZR-75-1, B4, B6, and
B6TE cells, similar to MDA-MB-231 cells (Fig. 3B). When
inoculated orthotopically in the mammary fat pad area, the tumors
formed by B6TC cells grew at a similar rate as B6TE tumors, but
faster than B6 tumors and slower than MDA-MB-231 tumors in the
absence of exogenous estrogen supplementation (Fig. 4). However,
in the presence of supplemented estrogen, the growth of B6TC
tumors was significantly inhibited, similar to that of MDA-MB-231
tumors, whereas the growth of B6 and B6TE tumors was stimulated
suggesting that B6TC cells behave more like ER negative breast
cancer cells than ER positive breast cancer cells.
B6TC cell induced more extensive bone metastases than
MDA-MB-231 cell
Since B6TC cell was derived from MDA-MB-231 cell, which is
known to generate osteolytic bone metastasis, we used an
intracardiac injection model of experimental metastasis to
compare their ability to induce bone metastasis. Female nude
mice were inoculated with MDA-MB-231 and B6TC cells through
the left ventricle of the heart. Bone metastases induced by both cell
lines were monitored by whole-mouse GFP imaging, as described
earlier [8], and PET and CT imaging. Bone metastases in the
mandibles by the B6TC and MDA-MB-231 cells as detected by
CT imaging (Fig. 5A i, ii, iv, and v) and PET imaging (Fig. 5A iii
and vi) revealed more extensive osteolytic metastases by B6TC
cells (Fig. 5A ii and iii) than by MDA-MB-231 cells (Fig. 5A v and
vi). Figures 5Ai and 5Aiv show the intact mandible bones without
metastases on the left side of the respective mouse inoculated with
either MDA-MB-231 cells or B6TC cells. Whole-mouse GFP
imaging revealed more extensive tibial metastases indicated by the
presence of GFP positive tumors in the B6TC group as shown with
a representative image in Fig. 5B in comparison to the MDA-MB-
231 group. Both B6TC and MDA-MB-231 cells also induced
osteolysis in the tibiae as detected by Faxitron X-ray imaging
(Fig. 5B). We also examined the tumor burden in stained histologic
sections of the femora and tibiae of mice inoculated with B6TC or
MDA231-MB-231 cells. Representative bone histology pictures
with or without metastatic tumor are shown in Fig. 5C.
Comparison of the percent incidence of different levels of tibial
tumor burden showed that 40% of the tibiae from the B6TC mice
had greater than 50% of its marrow replaced by tumor and
another 40% tibia was 100% filled with tumor in their marrow
whereas the incidences for the tibia from MDA-MB-231 mice for
50% and 100% filled with tumors were only 30% and 20%
respectively (Fig. 5D). In the B6TC group due to the extensive
metastases of tumor cells in the leg bones, seven mice became
paralyzed in the hind limbs compared to the three mice with
similar condition in the MDA-MB-231 group. These observations
suggest that B6TC cell has a higher potential in inducing osteolytic
bone metastases than MDA-MB-231 cell.
B6TC cell induced brain metastases
During the whole mouse imaging for GFP-expressing metastatic
tumors at Week 4 after intracardiac inoculation of the cancer cells,
we noticed tumors in the brain area of B6TC mice (Fig. 6Aa).
PET/CT imaging confirmed that the tumors are in the brain, not
in calvarial bone (Fig. 6Ab and c). After the termination of the
experiment, the brain was removed, bisected, and 10 sagittal
sections were prepared at 300-mm intervals through one
hemisphere. The sections were processed for either H&E staining
or for immunohistochemistry staining for GFP or human TP53.
The presence of brain metastases was confirmed by the presence
of tumor cells in the H&E stained brain sections (Fig. 6Ba), which
were confirmed to be human cancer cells since they expressed
GFP (Fig. 6Bb) and human TP53 (Fig. 6Bc). Whole mouse GFP
Figure 1. Tumorigenicity and metastatic potential of B4 and B6
cells. (A) Western blot analysis of ERa in the cell extracts of ZR-75-1, B4,
B6, and MDA-MB-231 cells. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) levels were also measured in cell lysates to show equal
sample loading. (B) B4 and B6 cells were separately inoculated into the
both sides of inguinal mammary fat pad (2610
6 cells) of 5-week-old
female athymic nude mice in presence of 17b-estradiol (E2) pellets
(0.72 mg/90 days) or placebo pellets. The tumor sizes were measured
with a caliper and tumor volumes were calculated with the equation V
=( L 6W
2) x 0.5, where L is length and W is width of a tumor. The
asterisk ‘‘*’’ indicates significant difference at P,0.05 between the mean
tumor volumes of B6-E2 and B6-placebo at the given time points. For
the B4 cell-inoculated mice, only the E2 group showed tumor, but not
the placebo group. (C) Representative pictures of lung metastasis of the
B4-E2, B6-Placebo and B6-E2 group as detected by GFP fluorescence.
doi:10.1371/journal.pone.0020473.g001
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mice had brain metastases whereas none of the MDA-MB-231
mice showed brain metastasis at the end of the fourth week
(Fig. 6C). On the other hand, we found that ZR-75-1 cells can
induce brain metastasis when inoculated through intracardiac
injection in the presence of exogenous estrogen supplementation
(Fig. S3) suggesting that the brain metastatic property of B6TC cell
may be derived from ZR-75-1 cell.
B6TC cell exhibits more prominent tumor stem cell
features than its parental cells
Cancer cells with high metastatic potential are believed to have
a higher population of cancer stem cells with epithelial to
mesenchymal transition properties. Being highly metastatic,
B6TC cells were found to express intermediate levels of CD44
and CD24 in comparison to its parental MDA-MB-231 and ZR-
75-1 cells (Fig. 7A). But, like MDA-MB-231 cell, it expressed high
levels of other stem cell markers including Vimentin, Integrin b1,
ALDH, and CXCR4 (Fig. 7A). On the other hand, similar to ZR-
75-1 cells, B6TC cells were capable of forming mammospheres
when the cells were suspended in a dedifferentiation medium
exhibiting cancer stem cell properties, whereas MDA-MB-231
cells were incapable of forming mammospheres which are
characteristic of these cells (Fig. 7B).
Discussion
It has been indicated previously that spontaneous cell fusion
between tumor cells or between tumor cells and bone marrow
derived stem cells might play an important role in the acquisition
of malignant phenotypes including aneuploidy, drug resistance,
and cancer stem cell features [9–11]. For example, fusion of two
cell lines, which were resistant to two different drugs, produced a
new cell line that was not only resistant to the two drugs, but also
resistant to an additional drug [12]. A recent study from Yibin
Kang’s group showed spontaneous cell fusion in vitro or in vivo
between two sublines of the MDA-MB-231 breast cancer cell line
with different metastasis organotropisms resulting in the formation
of a stable new cell line with dual metastasis organotropisms [4]. In
this study, we have generated an estrogen independent highly
malignant B6TC hybrid cell line, spontaneously formed between
an ERa positive and ERa negative cell, and isolated from a bone
marrow metastatic site. Since B6TC cells are much more
malignant than its prarental cells with a number of stem cell
characteristics, we speculate that it might be formed by the fusion
of at least one cell with stem cell features.
Our study was initiated to investigate whether the presence of
primary tumors formed by highly metastatic MDA-MB-231 or
MDA-MB-435 cells can drive less metastatic ZR-75-1 cell homing
to bone. In the process of characterizing bone metastatic ZR-75-1
cells, we identified the hybrid cell line, B6TC. Whether a specific
metastasis-permissive niche in the bone established by the primary
tumors might be involved in the generation of this hybrid cell line
would require further investigation. The B6TC cells originated
from B6 cells, which were generated in the bone marrow, and it
was composed of a mixed population of ER high and low cells with
marked differences in their proliferative potential and malignancy.
Among them, the low ER expressing B6TC cells are highly
metastatic. B6TC cell contains the identical p53
R280K mutation as
the MDA-MB-231 cell and in large part resembles MDA-MB-231
cell with respect to its growth property and response to estrogen.
However, its brain metastatic property and ability to form
mammospheres appears to resemble ZR-75-1 cell rather than
MDA-MB-231 cell. Gene expression profiling indicates that B6TC
Figure 2. Characterization of estrogen-independent B6TC cells. (A) Morphology of ZR-75-1, B6TC and MDA-MB-231 cells as detected under
bright field. (B) Western blot analysis in the cell extracts of the parental ZR-75-1, B6, B6TC and MDA-MB-231 control cells with antibodies to ER-a.
GAPDH levels were measured in cell lysates to show equal sample loading. (C) Representative immunocytochemical staining pictures for the
expression of ERa in ZR-75-1, B6TC and MDA-MB-231 cells were taken in confocal microscope under 60X magnification. (D) To confirm the expression
of a functional ERa, the cells were transiently cotransfected with an estrogen-responsive promoter-luciferase report plasmid (ERE-thymidine kinase-
Luciferase) and a b-gal expression plasmid. Cells were treated with 10
-7 M E2. Luciferase and b-gal activities in cell lysates were determined. Luciferase
activity normalized with b-gal activity is presented as the mean6SEM for each treatment from triplicate transfections. The asterisk ‘‘*’’ indicates
significant difference between the –E2 and +E2 groups with Student t tests at P,0.05.
doi:10.1371/journal.pone.0020473.g002
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cell. We are currently in the process of identifying genes that
contribute to the bone and brain metastatic property of B6TC cell.
The precise cellular and molecular mechanisms that lead to
metastases of a tumor to a pre-determined location are not known.
To specifically identify genes that mediate metastasis, animal
models have been used to select in vivo for highly metastatic and
organ specific derivatives of human cancer cell lines [13]. In this
study, the B6TC cells are highly metastatic to the bone as well as
to the brain. Bone is the most common site for cancer metastases.
Breast cancer metastasizes to bone in more than 80% of patients
with advanced disease [14]. Existing evidences suggest that
enhanced formation and activation of osteoclasts induced by
colonization of cancer cells are critical to the establishment of bone
metastases. B6TC cells consistently caused osteolytic bone
metastases in nude mice after intracardiac inoculation. This
model provides opportunity to study pathogenesis and molecular
mechanism of tumor cell-bone interactions in breast cancer
metastases. Our results demonstrate B6TC tumor causes increased
bone resorption, not counterbalanced by bone formation. Future
investigation is needed to define the role of different tumor
producing osteoclastogenic factors, which stimulates the differen-
tiation and activation of the osteoclasts, leading to the progression
of bone destruction in the steps of bone metastatic cascade of
B6TC cells. This model can be used in search of effective
treatment for osteoclastic bone metastasis.
The RNA microarray study for identifying genes that are
unique and overexpressed in B6TC cells compared to the parental
cell lines MDA-MB-231 and ZR-75-1 and characterization of
those genes with respect to their biological function will certainly
have great impact on our current understanding of metastasis.
Brain metastases are the most feared complication in breast
cancer. Nearly 20% of patients with advanced breast cancer are
eventually diagnosed with brain lesions, making breast tumors the
main source of metastatic brain disease in women [15–17].
Because of the availability of many advanced cancer therapeutics,
the life span of breast cancer patients has been increased.
However, presently available treatment regimens are not effective
in treating breast cancer brain metastases. Limited rodent model
systems have been reported for brain metastasis in breast
carcinoma [18,19]. Therefore, there is a need of efficient model
systems that can be utilized for our understanding of different
factors from both the host and the tumor contributing to brain
metastasis. Overexpression of the genes related to brain coloni-
zation in our B6TC model may reveal novel genes contributing to
the brain metastasis by comparing the signal pathways involved.
The brain tissues are well-protected by blood brain barrier [17].
Intravasation of such complex barrier occurs at a very low rate
compared to the intravasation in a lung capillary. Also, the unique
microenvironment present in the brain is relatively poorly
understood, but seems to be different from other organs and
may influence brain metastases [17,20,21]. There are reports that
CXCR4 may act as a signature gene in contributing to the
invasive and metastatic behavior of the breast cancer cells to the
brain [22]. Our gene profiling data also implicates CXCR4 in
brain metastasis as it is upregulated in B6TC in comparison to its
parental cells. The brain permeability is very important for drug
development [17,21]. The understanding of brain metastasis in
our B6TC model will provide insights into the development of
potential novel therapies for breast cancer-induced brain metas-
tasis, especially for the search of efficacious small inhibitors that
can cross the blood brain barrier.
Many solid tumor types, including breast cancer, exhibit a
functional hierarchy of cancer cells of which only a small
subpopulation of stem-like cells can give rise to the differentiated
cells that comprise the bulk tumor [23–28]. The cancer stem cell
hypothesis is very important concept in cancer biology and also for
the detection, prognosis and prevention of cancer. The develop-
ment of cancer therapeutics based on tumor regression may have
produced agents which kill differentiated tumor cells while sparing
the small cancer stem cell population [29]. Therefore development
of successful cancer therapeutic regimen requires targeting this
cancer stem cell population. Such cells represent a subpopulation
of cancer cells that, by one mechanism or another, have the
capacity to act as tumor-propagating cells [30,31]. In our study,
we show that B6TC cells express a high level of CD44+ and a low
level of CD242, a phenotype similar to the cancer stem cells. One
candidate stem cell marker with conserved stem and progenitor
cell functions is aldehyde dehydrogenase 1 (ALDH1), a detoxifying
enzyme responsible for the oxidation of intracellular aldehydes
[32–35]. It has been shown that murine and human hematopoietic
and neural stem and progenitor cells have a high ALDH activity
[36–39]. The B6TC cell populations show high expression of
ALDH. Since it has been shown that cells with high ALDH
activity contain the tumorigenic cell fraction, are able to self-
renew, and recapitulate the heterogeneity of the parental tumor
[40], B6TC cells likely have a population of cancer stem cells. The
formation of mammospheres by B6TC cells confirms that it has
breast cancer stem cells as mammospheres generated from normal
mammary epithelium are enriched in stem/progenitor cells [41].
Therefore, it will be of great interest to determine whether these
CD44+/CD242/ALDH+ cells are directly targeted by alternative
Figure 3. Comparison of in vitro growth property of B6TC cell
with other cells. (A) Cells were plated in a 96-well plate at 2,000 cells
per well. After 5 days of incubation, relative cell number in each well
was determined with MTT assay as reflected with absorbance at
595 nm. The data are presented as mean6SEM from four replicate
wells. (B) Anchorage independent growth property of the depicted cell
lines was compared with a soft agarose assay. The cells were suspended
in 0.4% soft agarose and plated at 1,000 cells per well. After 3 weeks of
incubation, the colonies were visualized with p-iodonitrotetrazolium
violet staining.
doi:10.1371/journal.pone.0020473.g003
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results, using B6TC model to target CD44+/CD242/ALDH+
cells for drug discovery offers a highly promising and reproducible
means to identify therapies that prevent self-renewal of cancer
stem cells in a tumor microenvironment.
In summary, our study shows that tumors formed by aggressive
ER-negative breast cancer cells can enhance metastatic potential
of less aggressive ER-positive breast cancer cell. Cell fusion may be
a unique mechanism of tumor heterogeneity. The estrogen-
independent highly malignant B6TC hybrid cell line with stem
cell-like properties, spontaneously formed between an ERa
positive and ERa negative cell and isolated from a bone marrow
metastatic site, will be useful for the investigation of the molecular
mechanism of brain metastasis and for the therapeutic targeting of
breast cancer cells resistant to anti-estrogens.
Materials and Methods
Ethics statement
All animal experiments were conducted following appropriate
guidelines. They were approved by the ethics committee/
institutional review board, ‘Institutional Animal Care and Use
Committee’ (IACUC approval ID 99142X3411A) and monitored
by the Department of Laboratory Animal Resources (DLAR) at
the University of Texas Health Science Center at San Antonio.
Cell lines and culture
MDA-MB-435-F-L/GFP cells, which are highly invasive and
metastatic variants of human carcinoma MDA-MB-435 cells, were
isolated in our laboratory [42]. The human breast cancer cell lines
ZR-75-1 was originally obtained from the American Type Culture
Collection (Manassas, VA) and stably transfected with the
enhanced green fluorescent protein (GFP) for the detection of
metastases in vivo with green fluorescence imaging. We used a
clone of GFP-transfected MDA-MB-231 cells named clone 10
from Dr. Julie Anne Sterling at Vanderbilt University, which was
resistant to G418 antibiotic. This clone, like its parent line,
induced lung metastases when growing orthotopically and both
lung and bone metastases when inoculated intracardiacally in our
preliminary tests, and is hereafter referred as MDA-MB-231 cell.
ZR-75-1/GFP cell was also stably transfected with a puromycin-
resistant gene expression vector and puromycin-resistant cells were
pooled and used in the experiments. These cell lines were cultured
in McCoy’s 5A medium supplemented with pyruvate, vitamins,
amino acids, antibiotics, and 10% fetal bovine serum, as previously
described [43], Working cultures were maintained at 37uCi na
humidified incubator with 5% CO2.
Antibodies
Antibody to the Estrogen Receptor alpha was from Labvision
Corporation (Fremont, CA), antibody to Vimentin was from
Sigma Aldrich (St. Louis, MO), antibody to CXCR4 was from
Abcam (Cambridge, MA), and antibodies to ALDH, CD44, CD24
and Integrin b1 were from Santa Cruz Biotechnology (Santa Cruz,
CA).
Western blot analysis
Cells were grown to confluence in 60-mm tissue culture dishes
and lysed in a buffer solution [50 mmol/L Tris-HCl (pH 7.4),
150 mmol/L NaCl, 0.5% NP40, and a protease inhibitor cocktail
from Pierce, Rockford, IL]. Equal amounts of protein were
separated on 10% or 7.5% SDS-PAGE gels and blotted onto
Figure 4. Comparison of in vivo tumorigenic property of B6TC cell with other cells. Exponentially growing tumor cells (2610
6) were
inoculated into both inguinal mammary fat pads of 5-week-old female athymic nude mice implanted subcutaneously with a 17b-estradiol (E2) pellet
(0.72 mg/90 days) or placebo pellet. The tumor sizes were measured with a caliper in two dimensions once every week after the growth of tumors
was observed. Tumor volume was the sum of two tumors in each mouse and calculated with the equation V = (L6W
2) x 0.5, where L is length and W
is width of a tumor. Values are mean 6 SEM of 5 mice in each group except the B6TE-E2 group, which had 4 mice. The asterisk indicates significant
difference between the growth curves with E2 or placebo pellets by a paired Student t test at P,0.05 (*) or P,0.1 (**).
doi:10.1371/journal.pone.0020473.g004
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ed with respective primary antibodies; mouse anti–glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; 1:10,000; Ambion, Inc.,
Austin, TX) was used as a loading control, horseradish
peroxidase–conjugated goat anti-rabbit (1:5,000; Santa Cruz
Biotechnology), and horseradish peroxidase–conjugated goat
anti-mouse (1:5,000; Santa Cruz Biotechnology) antibodies were
used as secondary antibodies.
TGF-b sensitivity assay
For the measurement of the transcriptional activity of TGF-ß
with a TGFß responsive promoter-luciferase construct, pSBE4-
Luc, cells were seeded at 2.0610
4 per well in 12-well plates. When
cells were ,80% confluent, they were cotransfected with 1.0 mgo f
pSBE4-Luc and 0.5 mg of a ß-galactosidase expression plasmid
using 4.5 mL of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in
serum-free medium following the manufacturer’s protocol. After
4 h, the medium was replaced with the serum-containing medium
and TGFß3 was added at 5.0 ng/mL. The cells were lysed after
overnight incubation in buffer (100 mmol/L K2HPO4, 1 mmol/L
DTT, and 1% Triton X-100) and the luciferase in the cell lysate
was measured as previously described [8]. Luciferase activity was
activity normalized for transfection efficiency by b-galactosidase
activity.
Cell proliferation assay
Cells were plated in 96-well plates at 1,600 cells/well. Relative
cell number in each well was determined every 24 h by MTT
assay as described previously [44].
Soft-Agarose assay
To determine the ability of the cell to grow anchorage-
independently in a semisolid medium, soft agarose assays were
performed as described previously [44]. Briefly, 6610
3 cells were
suspended in 1 ml of 0.4% low melting point agarose (Life
Technologies, Carlsbad, CA) dissolved in the regular culture
medium and plated on the top of a 1 ml underlayer of 0.8%
agarose in the same medium in 6-well culture plates. After 3–4
Figure 5. Comparison of bone metastatic potential between B6TC and MDA-MB-231 cells. B6TC and MDA-MB-231 cells were inoculated
through the left cardiac ventricle of female nude mice at 0.1610
6 cells/mouse. Osteolytic bone metastases induced by B6TC and MDA-MB-231 cells
were detected with various imaging methods. (A) Representative pictures of bone metastasis of the B6TC and MDA-MB-231 cells as detected by
microCT imaging. Panel ii shows an osteolytic metastasis in the right jaw of a B6TC mouse while the left jaw (Panel i) remained intact. Similarly Panel v
shows an osteolytic metastasis in the right jaw of a MDA-MB-231 mouse while the left jaw (Panel iv) remained intact. Axial PET/CT fused images are
shown in Panels iii and vi for the B6TC and MDA-MB-231 mice, respectively. (B) Metastases in tibia/femur were detected by whole mouse GFP
imaging as shown with a representative image for a B6TC mouse and a MDA-MB-231 mouse in the upper panels. Bone resorption due to osteolysis in
the tibia was detected with X-ray radiographs for the B6TC and MDA-MB-231 mice as shown in the lower panels respectively. (C) At the termination of
the experiment, the femora and tibiae were fixed in buffered formalin and decalcified. Paraffin-embedded sections were stained with hematoxylin,
eosin, orange G, and phloxine. Representative pictures of the stained tibial sections with tumor indicated by arrow and without tumor are shown in
the two panels respectively. (D) Mouse tibiae with tumor were divided into four groups and the results were expressed in percentage of tibiae with
,20% tibia replaced by tumor, with 20–50% tibia replaced by tumor, with .50% of tibia replaced by tumor, and with 100% of tibia replaced by
tumor.
doi:10.1371/journal.pone.0020473.g005
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37uC, the cell colonies were visualized by staining with 1 ml of p-
iodonitrotetrazolium violet staining (Sigma). Cell colonies were
counted.
Tumorigenicity and in vivo lung metastatic study
Four- to five-week-old female athymic nude mice (Harlan
Sprague Dawley, Inc., Indianapolis, IN) were used for in vivo
animal experiments. The animals were housed under specific
pathogen-free conditions. All animal protocols were approved and
monitored by the institutional animal care and use committee.
EGFP-expressing MDA-MB-435-F-L, MDA-MB-231, ZR-75-
1/puro cells and its variant lines B4, B6, and B6TC cells were
separately inoculated (2610
6 cells) into the both inguinal
mammary fat pad of 5-week-old female athymic nude mice. The
tumor sizes were measured with a caliper in two dimensions.
Tumor volumes were calculated with the equation V= (L6W
2)x
0.5, where L is length and W is width of a tumor. Animals were
sacrificed 4 or 6 weeks after tumor cell inoculation. The green
metastatic cancer cell colonies of different sizes were visually
observed, counted and measured in the whole lungs using NIKON
fluorescence microscope (TE-200) with a 20X objective (200X
magnification).
Establishment of cell lines from xenograft tumors
The orthotopic tumors formed by B6 cells in the presence or
absence of estrogen supplementation were excised from mice
inside a tissue culture hood and cut into 2–3 mm pieces in a
100 mm sterile Petri dish containing a serum-free (SM) medium.
The tumor tissues were transferred to a 50-ml tube containing
Figure 6. Brain metastasis induced by intracardiacally inoculated B6TC cells. (A) Representative pictures of brain metastases of the B6TC
cell-inoculated mice as detected by GFP whole mouse imaging (Panel a) and microPET/CT imaging (Panels b and c). (B) Brain metastatic B6TC cells
were detected with H&E staining (Panel a), immunohistochemical staining for GFP or TP53 as shown in Panels b and c, respectively. (C) Percentage of
brain metastases in B6TC and MDA-MB-231 groups as detected by the GFP imaging.
doi:10.1371/journal.pone.0020473.g006
Figure 7. Comparison of cancer stem cell features of B6TC cell
with its parental cells. (A) Western blot analysis for stem cell markers
of CD44, CD24, Vimentin, Integrin b1, ALDH, and CXCR4 in the cell
extracts of the ZR-75-1, B6TC and MDA-MB-231 cells. GAPDH levels
were measured for equal loading. (B) Formation of mammospheres by
the three cell lines in suspension culture with GFP imaging.
doi:10.1371/journal.pone.0020473.g007
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Blendzyme (Roche, Indianapolis, IN). The tube was incubated in a
CO2 incubator at 37uC for 30–45 minutes, vortexed at 10 min.
interval, filtered through a 70 micron membrane filter (Fisher) and
centrifuged at 500 g for 5 minutes at 4uC. The supernatant was
discarded and the cell pellet was resuspended and cultured in
McCoy’s 5A medium containing 10% fetal bovine serum. After 2–
3 days, medium was changed to the medium containing G418 to
kill the mouse cells and select for the cancer cells. The selected
B6TC and B6TE cells were cryopreserved in liquid N2 for future
use.
Experimental in vivo bone and lung metastasis assay
An intracardiac injection model for experimental bone
metastasis was used for this study, as previously described. Briefly,
MDA-MB-231, ZR-75-1, B6, B6TC cells were harvested from
subconfluent exponentially growing cultures. The cells were
injected into the left cardiac ventricle of anesthetized female nude
mice (5 weeks old) with a 27-gauge needle attached to a 1-ml
syringe using a micromanipulator. Each mouse was injected with
10
5 cells in 0.1 ml of phosphate-buffered saline, and successful
injections were indicated by the pumping of red blood into the
syringe. Development of bone metastasis induced by EGFP-
expressing cells was monitored at regular intervals by whole-
animal green fluorescence imaging to detect EGFP-expressing
tumor cells growing in the legs, arms, spine, and mandible bones,
using a Nikon SMZ1500 (Nikon, Tokyo, Japan) fluorescence
stereoscope attached to a CoolSNAP CCD camera (Photometrics,
Tucson, AZ). Radiographs taken with Faxitron (Lincolnshire, IL)
were used for the detection of any bone lesion in mice injected
with cancer cells. At the termination of experiment after about 4
weeks, whole lungs were excised, and EGFP-expressing metastatic
cancer cell colonies were visually observed and counted under an
inverted fluorescence microscope. Bone tissues were fixed in 10%
neutral-buffered formalin (Fisher Scientific, Houston, TX) for
24 hours at room temperature, decalcified in 10% EDTA, and
embedded in paraffin. Sections were stained with hematoxylin,
eosin, orange G, and phloxine, and the presence of metastatic
tumors and bone osteolysis in the femora and tibiae was examined
under a microscope.
Radiolabeling and quality control
Bevacizumab (Avastin, Genetech) are radiolabeled with posi-
tron emitter
64Cu (
64CuCl2 in 0.1 M HCl; radionuclide purity
.99%, University of Wisconsin). For radiolabeling, Wipke and
Wang’s method was applied [45,46]. Briefly, Bevacizumab was
reacted with a 100:1 molar ratio of DOTA-NHS-ester (1,4,7,
10-tetraazacyclododecane-N,N9,N0,N90-tetraacetic acid mono-N-
hydroxysuccinimide ester, M.W= 990 mg/mmol): antibody in
0.1 M Na2HPO4 buffer of pH 7.5 at 4uC for 12–16 h. After
conjugation, the reaction mixture was centrifuged repeatedly
through a YM-30 centricon with 0.1 M ammonium citrate buffer
of pH 6.5 in order to remove unconjugated small molecules. The
concentration of purified antibody-conjugate was determined by a
UV spectrophotometer measuring the absorbance at 280 nm.
Typically, 1 mg of DOTA-conjugated antibody and 5 mCi of
64Cu were incubated in 0.1 M ammonium citrate, pH 6.5, at
43uC for 45 minutes. Labeled antibody was separated by a size-
exclusion column (Bio-Spin6, BIO-RAD Laboratories, Hercules,
CA). Radiochemical purity of antibody was determined by
integrating areas on the Fast Protein Liquid Chromatography
(FPLC) with a size-exclusion column and measuring the
percentage of radioactivity associated with the 150 kDa protein
peak. The stability of the
64Cu radiolabeled molecules was
determined by bovine serum challenge at 24 hours.
Methods for MicroCT and
64Cu imaging
The distribution of
64Cu-bevacizumab was investigated in
B6TC bone metastasis nude mice model. Each mouse was
injected intravenously via a lateral tail vein with
64Cu-bevacizu-
mab at the dose of 200 mCi/40 mg mAb in 200 ml of saline. Mice
were scanned at 1, 4, 24, and 48 h after injection for microCT and
64Cu imaging. All the mice were anesthetized with 2–3%
isoflurane in 100% oxygen during injection and scanning. With
the mice kept prone on the bed of the Gamma Medica-Ideas
FLEX preclinical system, static PET images were acquired for 10
minutes at 1 and 4 h post-injection, 15 minutes at 24 h post-
injection, and 20 minutes at 48 h post-injection to monitor
64Cu-
bevacizumab distribution. The whole mouse was in the field of
view. MicroCT images (75 kVp, 0.25 mA, 360u rotation, 256
projections) were acquired before each PET imaging session using
fly mode to acquire quality image and decrease radiation dose to
the mice. The images were reconstructed by using the software
offered from Gamma Medica-Ideas Inc and were fused by Amira
based software VIVID.
Mammosphere culture
Cells were cultured as mammospheres in anchorage indepen-
dent conditions as described earlier [47]. Briefly, Single cells were
plated in ultralow attachment 24 well plates (Corning) at a density
of 10,000 viable cells/ml. Cells were grown in a serum-free
DMEM-F12 medium (Gibco, Carlsbad, CA) supplemented with
B27 (Invitrogen, Carlsbad, CA 1:50), 20 ng/ml EGF and 20 ng/
mL bFGF (BD Biosciences, San Jose, CA), and 4 mg/ml heparin
(Sigma). Culture medium contained 1% methyl cellulose to
prevent cell aggregation. Colonies were monitored microscopically
daily to ensure that they were derived from single cells.
Microarray processing
Total RNA was extracted from near confluent B6TC, MDA-
MB-231/GFP/Neo and ZR-75-1/GFP/puro cells. The RNA was
purified using a RiboPure Kit from Ambion following the
manufacturer’s suggested protocol. RNA quality and quantity
was ensured using the Bioanalyzer (Agilent, Inc., Santa Clara, CA)
and NanoDrop (Thermo Scientific.,Waltham, MA) respectively.
Per RNA labeling, 5 micrograms of total RNA was used in
conjunction with the Affymetrix recommended protocol, One-
Cycle Target Labeling and Control Reagents.
The hybridization cocktail containing the fragmented and
labeled cDNAs was hybridized to The Affymetrix GeneChipH
Human Genome U133 Plus 2.0 Array. The chips were washed
and stained by the Affymetrix Fluidics Station using the standard
format and protocols as described by Affymetrix. The probe arrays
were stained with streptavidin phycoerythrin solution (Molecular
Probes, Carlsbad, CA) and enhanced by using an antibody
solution containing 0.5 mg/mL of biotinylated anti-streptavidin
(Vector Laboratories, Burlingame, CA). An Affymetrix Gene Chip
Scanner 3000 was used to scan the probe arrays. Gene expression
intensities were calculated using the Gene Chip Operating
software 1.2 (GCOS 1.2, Affymetrix). Each cell line was done in
triplicate labeling and hybridization.
Cell files were used for the GC-corrected robust multichip
average (GC-RMA) to adjust for background and non-specific
binding and to normalize expression values across arrays. Non-
specific filtering was used to remove probe-sets that showed very
low expression levels across a majority of the arrays and little
differential variation across arrays. An empirical Bayes modified
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levels for each gene between cell lines, and we used the False
Discovery Rate method to adjust for multiple testing effects.
Hierarchical clustering was used to visualize patterns of signifi-
cantly down- and up-regulated genes across arrays. Expression
values are standardized prior to clustering. The joint solution is
displayed in a false color image called a heatmap that displays
gene clusters as rows and array clusters as columns. The red to
blue color scheme reveals the pattern of down- and up-regulated
genes that separate the cell lines. All analyses were conducted
using procedures in the R/Bioconductor suite [48]. All microarray
data is MIAME compliant and the raw data has been deposited in
the MIAME compliant database GEO (Accession number
GSE27515).
Supporting Information
Figure S1 A. Gene expression profile of B6TC, MDA-MB-231
and ZR-75-1 cells represented by heatmap. B. The results from
triplicate microarray chips revealed that B6TC cell has a different
gene expression profile from those of its two parent cell lines.
(TIF)
Figure S2 TP53 sequence comparison among the B6TC,
MDA-MB-231 and ZR-75-1 cells. Briefly, total RNA was
extracted from near confluent B6TC, MDA-MB-231, and ZR-75-
1 cells. The RNA was purified using a RiboPure Kit from Ambion
following the manufacturer’s suggested protocol. Total RNA
sample were reverse transcribed with random hexamers. The
cDNAs were amplified in PCR with TP53 sense and antisense.
The PCR product was purified using the PCR cleaning kit from
Qiagen (Hilden, Germany) and sequenced. The sequence shown
in figure is antisense sequence where TCT codes for Arginine
(found in wild type TP53 in ZR-75-1 cell) and TTT codes for
Lysine (found in mutated TP53 in MDA-MB-231 and B6TC cells).
(TIF)
Figure S3 Representative picture of brain metastasis
induced by ZR-75-1 cells as detected by GFP imaging. In
an intracardiac injection model, 0.1610
6 ZR-75-1 cells were
injected into the left cardiac ventricle of female nude mice
supplemented with a 17b-estradiol (E2) pellet. Two out of four
mice developed metastases to the brain as indicated by the
presence of green fluorescence metastatic lesions in the brain.
(TIF)
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